{
    "clinical_study": {
        "@rank": "73680", 
        "arm_group": [
            {
                "arm_group_label": "RO5508887", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This single-center, randomized, double-blind, placebo-controlled study will evaluate the\n      safety, pharmacokinetics and pharmacodynamics of RO5508887 in healthy volunteers. Volunteers\n      will receive multiple-ascending doses of RO5508887 or matching placebo. The anticipated time\n      on study treatment is 14 days."
        }, 
        "brief_title": "A Single-Center Study of RO5508887 in Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult healthy volunteers, >/=18 years of age\n\n          -  Body mass index (BMI) between 18 and 30 kg/m2 inclusive\n\n          -  Use of adequate contraception methods or surgically sterile\n\n        Exclusion Criteria:\n\n          -  Evidence of active or chronic disease\n\n          -  Regular consumption of drugs of abuse\n\n          -  Regular smoker (>5 cigarettes per day)\n\n          -  Infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C\n             (HCV)\n\n          -  History of significant allergic reactions\n\n          -  Abnormal blood pressure\n\n          -  Clinical significant abnormalities (e.g., cardiovascular, laboratory values)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664143", 
            "org_study_id": "WP28102", 
            "secondary_id": "2012-000280-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "RO5508887", 
                "description": "Multiple doses of RO5508887", 
                "intervention_name": "RO5508887", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Multiple doses of placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Strasbourg", 
                    "country": "France", 
                    "zip": "67064"
                }
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Center, Randomized, Investigator/Subject-Blind, Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety: incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664143"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Correlation of the age on pharmacokinetics of RO5508887", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Correlation of the age on pharmacodynamics of RO5508887", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Pharmacokinetics: plasma levels of RO5508887", 
                "safety_issue": "No", 
                "time_frame": "Predose and up to 144 hours post last dose, and at follow-up"
            }, 
            {
                "measure": "Pharmacodynamics: Plasma levels of amyloid deposition markers", 
                "safety_issue": "No", 
                "time_frame": "Predose and up to 144 hours post last dose"
            }, 
            {
                "measure": "Correlation of the age on safety of RO5508887", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}